{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:42:11Z","timestamp":1784634131439,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["1402-0008"],"award-info":[{"award-number":["1402-0008"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40261-024-01357-z","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:02:11Z","timestamp":1713938531000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety, Tolerability, and Pharmacokinetics of Oral BI 1358894 in Healthy Japanese Male Volunteers"],"prefix":"10.1007","volume":"44","author":[{"given":"Jangsoo","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-8817","authenticated-orcid":false,"given":"Akiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"Suppl 1","key":"1357_CR1","first-page":"S34","volume":"59","author":"S Gautam","year":"2017","unstructured":"Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical Practice guidelines for the management of depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-s50.","journal-title":"Indian J Psychiatry."},{"key":"1357_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1357_CR3","doi-asserted-by":"crossref","unstructured":"Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019 Dec 17;12:Cd010557.","DOI":"10.1002\/14651858.CD010557.pub2"},{"issue":"10","key":"1357_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1017\/S1461145711000083","volume":"14","author":"JM Dupuy","year":"2011","unstructured":"Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, Nierenberg AA. A critical review of pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol. 2011;14(10):1417\u201331.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"1357_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14737175.2017.1341310","volume":"17","author":"G Rakesh","year":"2017","unstructured":"Rakesh G, Pae CU, Masand PS. Beyond serotonin: newer antidepressants in the future. Expert Rev Neurother. 2017;17(8):777\u201390.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"1357_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1176\/appi.ajp.2013.13070852","volume":"171","author":"HW Koenigsberg","year":"2014","unstructured":"Koenigsberg HW, Denny BT, Fan J, Liu X, Guerreri S, Mayson SJ, et al. The neural correlates of anomalous habituation to negative emotional pictures in borderline and avoidant personality disorder patients. Am J Psychiatry. 2014;171(1):82\u201390.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1357_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1037\/a0035834","volume":"123","author":"D Mandell","year":"2014","unstructured":"Mandell D, Siegle GJ, Shutt L, Feldmiller J, Thase ME. Neural substrates of trait ruminations in depression. J Abnorm Psychol. 2014;123(1):35\u201348.","journal-title":"J Abnorm Psychol"},{"issue":"6","key":"1357_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000573","volume":"2","author":"MA Fowler","year":"2007","unstructured":"Fowler MA, Sidiropoulou K, Ozkan ED, Phillips CW, Cooper DC. Corticolimbic expression of TRPC4 and TRPC5 channels in the rodent brain. PLOS ONE. 2007;2(6):e573.","journal-title":"PLoS ONE"},{"issue":"4","key":"1357_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cell.2009.03.039","volume":"137","author":"A Riccio","year":"2009","unstructured":"Riccio A, Li Y, Moon J, Kim KS, Smith KS, Rudolph U, et al. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell. 2009;137(4):761\u201372.","journal-title":"Cell"},{"issue":"10","key":"1357_CR10","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1523\/JNEUROSCI.2274-13.2014","volume":"34","author":"A Riccio","year":"2014","unstructured":"Riccio A, Li Y, Tsvetkov E, Gapon S, Yao GL, Smith KS, et al. Decreased anxiety-like behavior and Galphaq\/11-dependent responses in the amygdala of mice lacking TRPC4 channels. J Neurosci. 2014;34(10):3653\u201367.","journal-title":"J Neurosci"},{"issue":"1","key":"1357_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191225","volume":"13","author":"S Just","year":"2018","unstructured":"Just S, Chenard BL, Ceci A, Strassmaier T, Chong JA, Blair NT, et al. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice. PLOS ONE. 2018;13(1):e0191225.","journal-title":"PLOS ONE"},{"issue":"12","key":"1357_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40263-023-01041-4","volume":"37","author":"R Fuertig","year":"2023","unstructured":"Fuertig R, Goettel M, Herich L, Hoefler J, Wiebe ST, Sharma V. Effects of single and multiple ascending doses of BI 1358894 in healthy male volunteers on safety, tolerability and pharmacokinetics: two phase I partially randomised studies. CNS Drugs. 2023;37(12):1081\u201397.","journal-title":"CNS Drugs"},{"key":"1357_CR13","doi-asserted-by":"crossref","unstructured":"Fuertig R, Goettel M, Van der Plas M, Schlieker L, Sharma V. P.449 Relative bioavailability of a single oral dose BI 1358894 administered alone or in combination with multiple oral doses of itraconazole. Eur Neuropsychopharmacol. 2020;40:S255-S6.","DOI":"10.1016\/j.euroneuro.2020.09.332"},{"key":"1357_CR14","doi-asserted-by":"crossref","unstructured":"ACNP 59th Annual Meeting: Poster Session II (T94). Neuropsychopharmacol. 2020;45(1):170\u2013277.","DOI":"10.1038\/s41386-020-00891-6"},{"key":"1357_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.10.009","volume":"65","author":"S Grimm","year":"2022","unstructured":"Grimm S, Keicher C, Paret C, Niedtfeld I, Beckmann C, Mennes M, et al. The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder. Eur Neuropsychopharmacol. 2022;65:44\u201351.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1357_CR16","doi-asserted-by":"crossref","unstructured":"Goettel M, Mack S, Fuertig R, Sharma V, Just S, Boer JD. P.448 BI 1358894 attenuates cholecystokinin tetrapeptide (CCK-4) induced anxiety and panic symptoms in healthy male volunteers. Eur Neuropsychopharmacol. 2020;40:S255.","DOI":"10.1016\/j.euroneuro.2020.09.331"},{"issue":"12","key":"1357_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40263-023-01042-3","volume":"37","author":"M Goettel","year":"2023","unstructured":"Goettel M, Fuertig R, Mack SR, Just S, Sharma V, Wunder A, et al. Effect of BI 1358894 on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety, panic symptoms, and stress biomarkers: a phase I randomized trial in healthy males. CNS Drugs. 2023;37(12):1099\u2013109.","journal-title":"CNS Drugs"},{"issue":"9","key":"1357_CR18","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/j.biopsych.2020.02.747","volume":"87","author":"M Goettel","year":"2020","unstructured":"Goettel M, H\u00f6fler J, Fuertig R, Sharma V, G\u00f6ttel M. First-in-human study of oral BI 1358894 in healthy male volunteers: a phase I study to investigate safety and tolerability. Biol Psychiatry. 2020;87(9):S289\u201390.","journal-title":"Biol Psychiatry"},{"key":"1357_CR19","doi-asserted-by":"crossref","unstructured":"Fuertig R, Goettel M, H\u00f6fler J, Sharma V. P.450 A phase I single-rising-dose study of oral BI 1358894 in healthy male volunteers: safety, pharmacokinetics and food effect. Eur Neuropsychopharmacol. 2020;40:S256-S7.","DOI":"10.1016\/j.euroneuro.2020.09.333"},{"key":"1357_CR20","unstructured":"US Department of Health and Human Services and Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Office of Training and Communications, Division of Drug Information, document HFD-240. Washington DC: DHHS and FDA, CDER; 2002."},{"key":"1357_CR21","doi-asserted-by":"crossref","unstructured":"Goettel M, Fuertig R, Wiebe S, Herich L, Sharma V. P.447 Multiple rising doses of oral BI 1358894 in healthy male volunteers: a phase I study investigating safety, tolerability and pharmacokinetics. Eur Neuropsychopharmacol. 2020;40:S254-S5.","DOI":"10.1016\/j.euroneuro.2020.09.330"},{"issue":"10","key":"1357_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0091270004268128","volume":"44","author":"K Kim","year":"2004","unstructured":"Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44(10):1083\u2013105.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01357-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01357-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01357-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:34:19Z","timestamp":1715405659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01357-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01357-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"13 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Boehringer Ingelheim (BI study number 1402-0008; NCT03875001). The funders of the study had a role in the study design, data analysis, data interpretation, and writing of the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AH is an employee of Nippon Boehringer Ingelheim Co., Ltd. JY was an employee of Nippon Boehringer Ingelheim Co., Ltd at the time of the study conduct. VS was an employee of Boehringer Ingelheim International GmbH at the time of the study conduct. Authors did not receive any direct compensation relating to the development of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study was carried out in accordance with the principles of the Declaration of Helsinki, the International Conference for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines, applicable regulatory requirements, and Boehringer Ingelheim standard operating procedures. The study protocol, the subject information form and the informed consent form were reviewed and approved by the institutional review board of the Souseikai Hakata Clinic, Fukuoka, Japan on 22 March 2019.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed written consent in accordance with ICH GCP and local procedures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The informed consent form included permission to publish.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JY, AH, and VS contributed to the study concept and design, and were responsible for data analyses and interpretation. All authors contributed towards the preparation of the manuscript, approved the final submitted version, and agreed to be listed as authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}